Exelixis
EXEL
#1574
Rank
โ‚น946.92 B
Marketcap
โ‚น3,383
Share price
2.76%
Change (1 day)
86.25%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of December 2024 : โ‚น196.24 Billion

According to Exelixis's latest financial reports the company has โ‚น196.24 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$โ‚น188.46 B-8.47%
2022-12-31$โ‚น205.91 B25.15%
2021-12-31$โ‚น164.53 B19.73%
2020-12-31$โ‚น137.42 B14.31%
2019-12-31$โ‚น120.22 B33.55%
2018-12-31$โ‚น90.02 B394.76%
2017-12-31$โ‚น18.19 B199.77%
2016-12-31$โ‚น6.06 B-164.86%
2015-12-31$-โ‚น9.36 Billion28.58%
2014-12-31$-โ‚น7.28 Billion-277.84%
2013-12-31$โ‚น4.09 B-74.79%
2012-12-31$โ‚น16.23 B238.53%
2011-12-31$โ‚น4.79 B-146.86%
2010-12-31$-โ‚น10.24 Billion34.68%
2009-12-31$-โ‚น7.6 Billion180.93%
2008-12-31$-โ‚น2.71 Billion-180.58%
2007-12-31$โ‚น3.35 B-16.38%
2006-12-31$โ‚น4.01 B55.65%
2005-12-31$โ‚น2.57 B17.49%
2004-12-31$โ‚น2.19 B-70.15%
2003-12-31$โ‚น7.35 B-12.85%
2002-12-31$โ‚น8.43 B-26.3%
2001-12-31$โ‚น11.44 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
โ‚น1.574 T 702.27%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น7.084 T 3,510.16%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น3.896 T 1,885.56%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.433 T 630.24%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น513.92 B 161.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.251 T 3,085.54%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น8.093 T 4,024.32%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น0.77 Billion-100.39%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.52 B-98.71%๐Ÿ‡บ๐Ÿ‡ธ USA